文献速递腹部泌尿生殖技术与安全CTMRPET

散发性原发性嗜铬细胞瘤:六种影像检查的前瞻性个体内比较

Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA).
PubMed 文献 · AJR Am J Roentgenol · 2021-08-25

该前瞻性研究对14例经手术病理确诊的散发性原发性嗜铬细胞瘤患者,在3个月内完成68Ga-DOTATATE PET/CT、FDG PET/CT、18F-FDOPA PET/CT、18F-FDA PET/CT、CT和MRI的个体内比较。结果显示18F-FDOPA PET/CT和MRI的阳性率均为100%,18F-FDOPA PET/CT病灶-肝脏SUVmax比值最高(10.5),支持其作为首选一线影像方法。

要点

  • 18F-FDOPA PET/CT诊断散发性嗜铬细胞瘤的阳性率最高(100%),病灶-肝脏SUVmax比值达10.5。
  • MRI阳性率亦为100%,可作为无辐射的替代或补充检查。
  • 18F-FDA仍为实验性示踪剂,68Ga-DOTATATE和FDG阳性率均仅78.6%,CT最低66.7%。

关键影像表现/征象

  • 18F-FDOPA PET/CT的平均病灶显著度评分为5.0±0.0,为所有检查中最高。
  • MRI平均显著度评分为4.7±0.5,18F-FDA PET/CT为4.6±0.8,68Ga-DOTATATE PET/CT为4.4±1.0。
  • CT平均显著度评分为4.3±1.0,FDG PET/CT最低为4.1±1.5。

诊断标准与关键数值

  • 18F-FDOPA PET/CT对嗜铬细胞瘤的阳性率为100.0%(11/11)。
  • MRI阳性率为100.0%(12/12)。
  • 18F-FDA PET/CT阳性率为85.7%(6/7)。
  • FDG PET/CT和68Ga-DOTATATE PET/CT阳性率均为78.6%(11/14)。
  • CT阳性率为66.7%(8/12)。

临床应用与阅片要点

  • 对临床怀疑散发性嗜铬细胞瘤的患者,可优先考虑18F-FDOPA PET/CT进行定位诊断。
  • 若无18F-FDOPA或存在禁忌,MRI可作为阳性率高的替代检查。
  • 68Ga-DOTATATE、FDG PET/CT和CT的阳性率相对较低,阴性结果不能除外嗜铬细胞瘤。

局限性

  • 样本量小(仅14例),可能影响统计效能和结论外推。
  • 部分检查未在所有患者中完成(18F-FDOPA 11例、18F-FDA 7例、CT和MRI各12例),存在不完整配对。
  • 研究仅纳入散发性原发性嗜铬细胞瘤,未涉及遗传性、复发性或转移性病变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Recent professional society guidelines for radionuclide imaging of sporadic pheochromocytoma (PHEO) recommend 18F-fluorodihydroxyphenylala-nine (18F-FDOPA) as the radiotracer of choice, deeming 68Ga-DOTATATE and FDG to be second- and third-line agents, respectively. An additional agent, 18F-fluorodopamine (18F-FDA), remains experimental for PHEO detection. A paucity of research has performed head-to-head comparison among these agents. OBJECTIVE. The purpose of this study was to perform an intraindividual comparison of 68Ga-DOTATATE PET/CT, FDG PET/CT, 18F-FDOPA PET/CT, 18F-FDA PET/CT, CT, and MRI in visualization of sporadic primary PHEO. METHODS. This prospective study enrolled patients referred with clinical suspicion for sporadic PHEO. Patients were scheduled for 68Ga-DOTATATE PET/CT, FDG PET/CT, 18F-FDOPA PET/CT, 18F-FDA PET/CT, whole-body staging CT (portal venous phase), and MRI within a 3-month period. PET/CT examinations were reviewed by two nuclear medicine physicians, and CT and MRI were reviewed by two radiologists; differences were resolved by consensus. Readers scored lesions in terms of confidence in diagnosis of PHEO (1-5 scale; 4-5 considered positive for PHEO). Lesion-to-liver SUVmax was computed using both readers' measurements. Interreader agreement was assessed using intraclass correlation coefficients (ICCs) for SUVmax. Analysis included only patients with histologically confirmed PHEO on resection. RESULTS. The analysis included 14 patients (eight women, six men; mean age, 52.4 ± 16.8 [SD] years) with PHEO. Both 68Ga-DOTATATE PET/CT and FDG PET/CT were completed in all 14 patients, 18F-FDOPA PET/CT in 11, 18F-FDA PET/CT in 7, CT in 12, and MRI in 12. Mean conspicuity score for PHEO was 5.0 ± 0.0 for 18F-FDOPA PET/CT, 4.7 ± 0.5 for MRI, 4.6 ± 0.8 for 18F-FDA PET/CT, 4.4 ± 1.0 for 68Ga-DOTATATE PET/CT, 4.3 ± 1.0 for CT, and 4.1 ± 1.5 for FDG PET/CT. The positivity rate for PHEO was 100.0% (11/11) for 18F-FDOPA PET/CT, 100.0% (12/12) for MRI, 85.7% (6/7) for 18F-FDA PET/CT, 78.6% (11/14) for FDG PET/CT, 78.6% (11/14) for 68Ga-DOTATATE PET/CT, and 66.7% (8/12) for CT. Lesion-to-liver SUVmax was 10.5 for 18F-FDOPA versus 3.0-4.2 for the other tracers. Interreader agreement across modalities ranged from 85.7% to 100.0% for lesion positivity with ICCs of 0.55-1.00 for SUVmax measurements. CONCLUSION. Findings from this small intraindividual comparative study support 18F-FDOPA PET/CT as a preferred first-line imaging modality in evaluation of sporadic PHEO. CLINICAL IMPACT. This study provides data supporting current guidelines for imaging evaluation of suspected PHEO. TRIAL REGISTRATION. ClinicalTrials.gov NCT00004847.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Jha A, Patel M, Carrasquillo JA, et al. Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA). AJR Am J Roentgenol. 2021. PMID: 34431366. doi:10.2214/AJR.21.26071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。